Aimco Pesticides LtdQ3 FY25
Aimco Pesticides Ltd Q3 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹55.1Market Cap: ₹57 CrSector: Fertilizers & Agrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- →Target revenue for FY26: Over ₹210 crore (Ashit Dave on Q4 and FY26 outlook).
- →Brand business revenue target for FY26: ₹200 crore (aim to double in two years).
- →Volume growth expectation: 15-20% increase year-on-year.
- →Export to domestic sales ratio currently ~50:50, with expectation of export business improvement in FY26.
- →New products: Three recently commercialized molecules expected to generate significant revenue from next financial year.
- →Capacity utilization: Currently around 70%, with plans to repurpose insecticide plant and consider additional capacity in Q4 FY25.
- →Bifenthrin capacity to be fully utilized in next two financial years, driven by Brazil market entry.
- →Overall growth dependent on pricing, market conditions, and regulatory registrations, especially in Brazil.
- →EBITDA margin expected to remain stable or improve with new high-margin branded products.
Margin guidance
Category 3- →Aimco Pesticides expects to be profitable by the end of FY25, with improving Q3 and Q4 performance.
- →Revenue target for FY25 is over ₹210 crore, with EBITDA margins expected to improve, though Q4 pricing remains uncertain.
- →For FY26, a clearer revenue and EBITDA margin target will be shared next quarter; branded business aims for ₹200 crore revenue by FY26.
- →The company plans 15-20% volume growth annually over the next couple of years, aided by new product launches and export market expansion.
- →Gross margins for branded formulations are stable at 30-35%, with EBITDA margins around 10%, expected to sustain as product mix improves.
- →New products commercial ramp-up and export registrations (e.g., Triclopyr in Brazil in FY26) should enhance growth.
- →Capex remains cautious to preserve cash flow, focusing on repurposing existing plants for new products with major capacity expansions deferred till profitability stabilizes.
3 more insights locked — sign up free to unlock
Fundraise plans
- →Currently, there is no mention of any ongoing or planned fundraising through debt or equity.
- →The company has put major Capex plans on hold to avoid burdening cash flow during difficult times.
- →Future Capex decisions, including investments in additional manufacturing capacity, will be taken cautiously after stabilizing profitability and margins.
- →Any large investments or capacity expansions will be evaluated and decided by the board at appropriate times.
- →No specific plans for raising funds via equity or debt have been disclosed for FY25 or FY26.
Order book
- →Significant orders are ongoing in Q3, with volume-wise expectations being satisfactory.
- →Q4 order projections are uncertain due to pricing and supply issues, especially from China.
- →Negotiations for new export contract products, including a herbicide, are ongoing but not finalized.
- →Discussions for Bifenthrin volumes in Brazil are active, expecting significant volume in Q4 and full capacity utilization by FY26.
- →Three new products are commercialized and early stage sales have started; significant ramp-up expected in next financial year.
- →The company's export orderbook faces pressure from price erosion and competition but volume remains steady.
- →Domestic brand business order momentum is strong and growing with expected revenue of ₹130 crore for FY25 and ₹200 crore by FY26.
- →Additional capacity decisions for new molecules pending and to be finalized next quarter.
Capex plans
Yes- →Current Capex is on hold to avoid burdening cash flow during difficult times; focus is on stabilizing existing business first.
- →Planned Capex for FY25 includes ₹1.5 to 2 crores to repurpose existing manufacturing facilities for a new product (modification and debottlenecking).
- →Major Capex proposals (formulation plant and intermediate plant with ~2000 tons capacity) have been deferred to FY26 or beyond, pending profitability and margin improvement.
- →Two new formulation plants have been acquired; setting up of a new formulation plant expected next year to add capacity, not to shift existing plant.
- →Additional capacity decisions for three new molecules will be made in Q4 FY25 based on market conditions.
- →Large-scale capacity expansions for new products anticipated in FY26 after product registrations and market demand improve.
- →Board to evaluate and approve any major future plant capacity investments carefully.
How does Aimco Pesticides Ltd rank vs peers in Fertilizers & Agrochemicals?
Pro feature1Aimco Pesticides Ltd
Rev 3Mar 3
See full Fertilizers & Agrochemicals sector rankings
